Xylonix IP Holdings

Xylonix is a clinical-stage biotechnology company focused on developing first-in-class immuno-oncology therapies that target the tumor microenvironment. The company's lead program, XYX-001, is a small molecule inhibitor designed to block the pro-tumorigenic effects of Interleukin-1 alpha (IL-1α) and Interleukin-1 beta (IL-1β) to reprogram tumor-associated macrophages. By neutralizing these key inflammatory drivers, Xylonix aims to overcome immune resistance and enhance the efficacy of existing cancer treatments. The company utilizes its proprietary 0X-Targeting platform to identify and develop therapies that specifically modulate the immune landscape of solid tumors.